DS
BXRX

David Shaw’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

David Shaw’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,880
Closed -$416K – 6055
2022
Q1 		$416K Buy
+5,880
New +$1.09M ﹤0.01% 4477
2021
Q4 		– Sell
-23
Closed -$18K – 5873
2021
Q3 		$18K Sell
23
-7
-23% -$6.09K ﹤0.01% 4905
2021
Q2 		$32K Buy
+30
New +$39.3K ﹤0.01% 4662
2021
Q1 		– Sell
-95
Closed -$134K – 4637
2020
Q4 		$134K Buy
+95
New +$194K ﹤0.01% 3782
2020
Q2 		– Sell
-34
Closed -$118K – 4336
2020
Q1 		$118K Sell
34
-23
-40% -$217K ﹤0.01% 3762
2019
Q4 		$556K Buy
+57
New +$486K ﹤0.01% 3340

Other funds holding BXRX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

David Shaw's BXRX Position: Q2 2022 in Review

David Shaw sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2022, closing a stake of 5,880 shares — an estimated $416K sold.

David Shaw first reported a position in BXRX in Q4 2019 and held it in 6 quarters. The position peaked at $556K in Q4 2019. 19 funds tracked by Wall St. Rank hold BXRX as of Q2 2022.

  • David Shaw reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 5,880 Baudax Bio, Inc. Common Stock shares in Q2 2022, an estimated $416K.
  • David Shaw first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • David Shaw's Baudax Bio, Inc. Common Stock position peaked at $556K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.